https://www.selleckchem.com/pr....oducts/pyrotinib.htm
Mitral regurgitation (MR), the second most common valvular heart disease, still constitutes a major diagnostic and thera-peutic challenge, due to its complex nature and to its consequences on cardiac remodelling. Life quality and expectancy are determined by the irreversibility of the left ventricular systolic dysfunction, which, despite current guidelines, remains a major drawback. In order to accurately establish "the point of no return" for left ventricular systolic function, the embedment of clinical, biological and imaging data i